JP2020514338A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514338A5
JP2020514338A5 JP2019548663A JP2019548663A JP2020514338A5 JP 2020514338 A5 JP2020514338 A5 JP 2020514338A5 JP 2019548663 A JP2019548663 A JP 2019548663A JP 2019548663 A JP2019548663 A JP 2019548663A JP 2020514338 A5 JP2020514338 A5 JP 2020514338A5
Authority
JP
Japan
Prior art keywords
compound
muscle
disease
salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019548663A
Other languages
English (en)
Japanese (ja)
Other versions
JP7761371B2 (ja
JP2020514338A (ja
Filing date
Publication date
Priority claimed from GBGB1703735.9A external-priority patent/GB201703735D0/en
Priority claimed from GBGB1706594.7A external-priority patent/GB201706594D0/en
Priority claimed from GBGB1707861.9A external-priority patent/GB201707861D0/en
Application filed filed Critical
Priority claimed from PCT/EP2018/055788 external-priority patent/WO2018162650A1/en
Publication of JP2020514338A publication Critical patent/JP2020514338A/ja
Publication of JP2020514338A5 publication Critical patent/JP2020514338A5/ja
Priority to JP2023076848A priority Critical patent/JP2023100869A/ja
Application granted granted Critical
Publication of JP7761371B2 publication Critical patent/JP7761371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019548663A 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法 Active JP7761371B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076848A JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1703735.9 2017-03-08
GBGB1703735.9A GB201703735D0 (en) 2017-03-08 2017-03-08 Methods for improving mitophagy in subjects
GBGB1706594.7A GB201706594D0 (en) 2017-04-25 2017-04-25 Methods for improving mitophagy in subjects
GB1706594.7 2017-04-25
GBGB1707861.9A GB201707861D0 (en) 2017-05-16 2017-05-16 Methods for improving mitophagy in subjects
GB1707861.9 2017-05-16
PCT/EP2018/055788 WO2018162650A1 (en) 2017-03-08 2018-03-08 Methods for improving mitophagy in subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076848A Division JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Publications (3)

Publication Number Publication Date
JP2020514338A JP2020514338A (ja) 2020-05-21
JP2020514338A5 true JP2020514338A5 (https=) 2021-04-22
JP7761371B2 JP7761371B2 (ja) 2025-10-28

Family

ID=61691936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548663A Active JP7761371B2 (ja) 2017-03-08 2018-03-08 対象におけるマイトファジーを改善するための方法
JP2023076848A Pending JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076848A Pending JP2023100869A (ja) 2017-03-08 2023-05-08 対象におけるマイトファジーを改善するための方法

Country Status (4)

Country Link
US (1) US20180256538A1 (https=)
EP (2) EP4553071A3 (https=)
JP (2) JP7761371B2 (https=)
WO (1) WO2018162650A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods
JP7761372B2 (ja) * 2017-03-08 2025-10-28 アマゼンティス エスアー 対象におけるマイトファジーを改善するための方法
US20230041432A1 (en) * 2019-03-21 2023-02-09 Fonterra Co-Operative Group Limited Compositions comprising polar lipids for maintaining or increasing mobility and vitality
CA3150587A1 (en) * 2019-09-25 2021-04-01 Societe Des Produits Nestle S.A. Compositions and methods using adenosylcobalamin
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
EP4065102A1 (en) * 2019-11-27 2022-10-05 Société des Produits Nestlé S.A. Benzocoumarin ampk activator compounds, compositions, methods and uses thereof
JP2023503276A (ja) * 2019-11-27 2023-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ａｍｐｋ間接活性化化合物と組み合わせたａｍｐｋ直接活性化化合物、組成物、方法、及びそれらの使用
CA3206062A1 (en) * 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
US20240307320A1 (en) * 2021-07-08 2024-09-19 Biophagy, Inc. A System and Method for Measuring and Stimulating Autophagy
KR102677423B1 (ko) * 2021-09-17 2024-06-21 조선대학교산학협력단 망기페린을 포함하는 자가포식 활성화용 조성물
EP4452259A1 (en) * 2021-12-20 2024-10-30 Société des Produits Nestlé S.A. Compositions comprising urolithin for treating muscle decline and a kidney dysfunction
JP2025510123A (ja) 2022-03-22 2025-04-14 アマゼンティス エスアー 組成物
CN115607671A (zh) * 2022-10-26 2023-01-17 深圳大学 一种提高运动皮层尿石素a浓度的方法及应用
EP4712958A2 (en) * 2023-05-18 2026-03-25 Vandria SA Use of urolithin derivatives in the treatment of amyotrophic lateral sclerosis
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073612A2 (en) * 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
WO2009137859A1 (en) * 2008-05-15 2009-11-19 Alois Jungbauer Compounds for the treatment of metabolic syndrome and insulin resistance
JP6054301B2 (ja) * 2010-12-23 2017-01-11 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
DK4233858T3 (da) * 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
GB201323008D0 (en) * 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP7761372B2 (ja) * 2017-03-08 2025-10-28 アマゼンティス エスアー 対象におけるマイトファジーを改善するための方法
US20180256471A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Skin Treatment Methods

Similar Documents

Publication Publication Date Title
JP2020514338A5 (https=)
JP2020510678A5 (https=)
EP3426240B1 (en) Mixed salt compositions for producing elevated and sustained ketosis
US11969411B2 (en) Administration of berberine metabolites
EP3873442B1 (en) A composition for weigth loss or weight management comprising beta-hydroxybutyrate and cannabidiol
KR102100091B1 (ko) 영양 조성물
JP2023100869A5 (https=)
EP2301530A1 (en) Use of a fatty acid composition comprising EPA and DHA for reducing body weight
JP5714227B2 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
JP2023100870A5 (https=)
US20120177623A1 (en) Compositions for Boosting Metabolism, Assisting Weight Loss, and Promoting Cardiovascular Health
KR20250105691A (ko) 15-hepe를 포함하는 조성물 및 그의 사용 방법
CN101842103A (zh) 用于脑部健康的单位剂量
AU2008301694B2 (en) Compositions Containing Sesamin-Class Compound(s) and Arachidonic Acid Class Compound(s)
CN103648494A (zh) 在降低氧化应激中的dha和epa
CN102302155A (zh) 云南大叶种茶树籽油软胶囊
CN105828623B (zh) 富含芝麻素类的组合物
CN103919774A (zh) 去亚甲基小檗碱在制备降血脂药物中的应用
US20170035728A1 (en) Compositions for Improved Body Composition
US12533346B2 (en) Administration of berberine metabolites
EP4637740A1 (en) Combinations of a urothilin and a ketone body
CN110139645A (zh) 用于预防和/或治疗恶病质的ω-3脂肪酸组合物
CA2842767A1 (en) Compositions of alpha-lipoic acid and curcumin for improved body composition
HK1225232B (zh) 富含芝麻素类的组合物